UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
OpenAI Restricts Astra AI Over Cyberattack Risks 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
SEATTLE, March 06, 2018 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the 38th Annual Cowen Healthcare Conference in Boston.
Brad Gray, president and chief executive officer, is scheduled to present on Tuesday, March 13, 2018 at 11:20am ET. Interested parties can access the live webcast with accompanying slides from the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 60 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,900 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, 3D Biology, 3D Flow, nCounter, PanCancer IO360 and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact:
Doug Farrell
Vice President, Investor Relations & Corporate Communications
[email protected]
Phone: 206-602-1768
